Analysts Issue Forecasts for Cingulate Q1 Earnings

Cingulate Inc. (NASDAQ:CING) – Equities research analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for Cingulate in a report issued on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will post earnings of ($0.37) per share for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.39) EPS.

Cingulate (NASDAQ:CING) last announced its earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.28).

Other equities research analysts have also recently issued reports about the stock. Roth Mkm reduced their target price on shares of Cingulate from $16.00 to $14.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Cingulate in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $34.50.

Cingulate Trading Down 2.7%

Shares of Cingulate stock opened at $5.35 on Tuesday. Cingulate has a 1 year low of $3.20 and a 1 year high of $11.89. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.16 and a current ratio of 1.16. The company has a market capitalization of $62.22 million, a P/E ratio of -1.24 and a beta of -0.76. The company’s fifty day moving average is $6.75 and its two-hundred day moving average is $5.12.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in Cingulate by 283.1% in the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after purchasing an additional 5,543 shares in the last quarter. Soltis Investment Advisors LLC purchased a new position in shares of Cingulate during the 4th quarter worth approximately $43,000. XTX Topco Ltd acquired a new stake in shares of Cingulate in the 2nd quarter valued at approximately $45,000. Quantum Private Wealth LLC lifted its holdings in shares of Cingulate by 140.0% in the 3rd quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after buying an additional 14,000 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in shares of Cingulate in the fourth quarter valued at approximately $66,000. 41.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Peter J. Werth acquired 19,455 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average cost of $5.04 per share, for a total transaction of $98,053.20. Following the transaction, the director directly owned 117,449 shares in the company, valued at approximately $591,942.96. This represents a 19.85% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Shane J. Schaffer acquired 6,809 shares of the company’s stock in a transaction on Friday, February 6th. The stock was purchased at an average cost of $5.04 per share, for a total transaction of $34,317.36. Following the completion of the purchase, the chief executive officer directly owned 10,175 shares in the company, valued at $51,282. This trade represents a 202.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 33,074 shares of company stock worth $166,693. 4.33% of the stock is currently owned by insiders.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.